What drove the SKIN.SW stock surge today?

High relative volume (2,756 vs avg 1,818) and renewed investor interest in Cassiopea’s dermatology pipeline drove the **9.85%** intraday gain. Traders reacted to clinical programme progress and improved intraday technicals that pushed price above the 50-day average.

What is Meyka AI’s grade for SKIN.SW stock?

Meyka AI rates SKIN.SW with a score out of 100: **62.51** | **Grade B** | **Suggestion: HOLD**. The grade blends benchmark, sector, growth and key metrics. Grades are informational and not financial advice.

What price target does Meyka AI forecast for SKIN.SW stock?

Meyka AI's forecast model projects **CHF42.50**, implying **19.05%** upside from the current **CHF35.70**. Forecasts are model-based projections and not guarantees. Confirm with company updates before trading.

How should traders manage risk on SKIN.SW stock?

Use tight stops near **CHF32.00** and size positions for low liquidity. Monitor volume to confirm breakouts above **CHF36.00** and watch clinical headlines. Avoid oversized exposure given negative earnings and binary biotech risks.

CH Stocks

+9.85% close: SKIN.SW Cassiopea S.p.A. (SIX) market closed, next steps

ByDanny Kontos February 25, 2026February 25, 2026

SKIN.SW stock led today’s high-volume movers on the SIX, closing at CHF35.70, up 9.85% on volume of 2,756 shares as the market closed on 24 Feb 2026. The move pushed price above the 50-day average CHF34.37 and below the 200-day average CHF37.22, highlighting short-term buying interest. Traders noted a day range of CHF32.00–CHF36.00, lifting volatility after several quiet sessions. This article breaks down the trading drivers, financials, technicals, risks and a model-based forecast to help frame near-term scenarios for SKIN.SW stock.